TRxADE HEALTH, Inc.
TAMPA, FL / ACCESSWIRE / July 21, 2021 / TRxADE HEALTH INC. (NASDAQ:MEDS) an integrated drug procurement, delivery, and healthcare platform, today announced that Bonum Health, a Digital Healthcare business subsidiary has signed a Telemedicine Service Distribution Deal with Southeastern Grocers Inc., parent company of Winn-Dixie, Harveys Supermarket and Fresco y Más grocery stores throughout the five states of Florida, Alabama, Louisiana, Georgia and Mississippi.
Bonum Health will provide affordable telemedicine services and prescription discount savings to the patients of all Winn-Dixie, Harveys and Fresco y Más retail stores and pharmacies by offering Bonum Health's signature Mobile Health Services application and prescriber program, staffed by over 600 board-certified medical providers. The partnership also provides Winn-Dixie patients direct access to prescription discount savings through Bonum Health signature telemedicine application, which can be downloaded from both the Google Play and App Store. According to Becker's Hospital Review, in 2020, approximately 5.4 million Americans lost their health insurance between February-May 2020 due to Covid-19 related lay-offs or job losses. This is a disturbing trend across America where the total number of uninsured has climbed to 21%. In the states that Winn-Dixie serves customers, the uninsured totals represent an average of 21% of all consumers across Florida, Georgia, Mississippi and Louisiana.
"Our strategic partnership with Bonum Health provides a fully integrated, deeply discounted and a patient-ready digital healthcare solution that gives eligible customers access to a Board-Certified Medical Provider," said Gayle Shields, Vice President of Pharmacy for Southeastern Grocers. "Bonum Health will help us diversify our in-store and community digital healthcare services as we offer deeply discounted telemedicine, with a combined prescription savings program designed into the same platform."
Ashton Maaraba, President of Bonum Health noted, "We are proud to support the Winn-Dixie, Harvey's and Fresco y Más retail store and pharmacy community. Winn-Dixie is committed to promote low-cost, turn-key, and innovative digital healthcare services across their consumer market. In working with Winn-Dixie, we plan on driving a seamless, deeply discounted and easily accessible digital health and wellness strategy. Our healthcare platform, medical providers, proprietary AI tools and resources not only offer fast and easy access to "live" virtual interactions with Board-Certified Medical Providers, but Winn-Dixie patients can also receive up to 80% savings on prescriptions."
About TRxADE HEALTH, INC.
TRxADE HEALTH (NASDAQ:MEDS) is a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.S. The Company operates the TRxADE drug procurement marketplace serving a total of 12,100+ members nationwide, fostering price transparency and under the Bonum Health brand, offering patient centric telehealth services. For info on TRxADE HEALTH, please visit the Company's IR website at investors.trxadegroup.com.
About Winn Dixie (Southeastern Grocers Inc.)
Founded in 1925, Winn-Dixie grocery stores, liquor stores and in-store pharmacies serve communities throughout five southeastern states - Alabama, Florida, Georgia, Louisiana and Mississippi. Winn-Dixie Stores, Inc. is a subsidiary of Southeastern Grocers, which is one of the largest supermarket chains based in the Southeast. For more information, please visit www.winndixie.com and www.segrocers.com.
Forward-Looking Statements
This press release may contain forward-looking statements, including information about management's view of TRxADE's future expectations, plans and prospects, within the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 (the "Act"). In particular, when used in the preceding discussion, the words "may," "could," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," "continue," "likely," "will," "would" and variations of these terms and similar expressions, or the negative of these terms or similar expressions are intended to identify forward-looking statements within the meaning of the Act, and are subject to the safe harbor created by the Act. Any statements made in this news release other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of TRxADE, its divisions and concepts to be materially different than those expressed or implied in such statements. These risks include risks relating to the adoption of our MedCheks app by partners and end-users, the apps of other competitors, including governments which may make certain apps mandatory or free, our ability to gain traction for our app in the marketplace, and the continued demand for our app; risks related to our operations not being profitable; claims relating to alleged violations of intellectual property rights of others; our ability to monetize our technological solutions; technical problems with our websites, apps and products; risks relating to implementing our acquisition strategies; our ability to manage our growth; negative effects on our operations associated with the opioid pain medication health crisis; regulatory and licensing requirement risks; risks related to changes in the U.S. healthcare environment; the status of our information systems, facilities and distribution networks; risks associated with the operations of our more established competitors; regulatory changes; healthcare fraud; COVID-19, governmental responses thereto, economic downturns and possible recessions caused thereby; changes in laws or regulations relating to our operations; privacy laws; system errors; dependence on current management; our growth strategy; and others that are included from time to time in filings made by TRxADE with the Securities and Exchange Commission, including, but not limited to, in the "Risk Factors" sections in its Form 10-Ks and Form 10-Qs and in its Form 8-Ks, which it has filed, and files from time to time, with the U.S. Securities and Exchange Commission. These reports are available at www.sec.gov. Other unknown or unpredictable factors also could have material adverse effects on TRxADE's future results and/or could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements. The forward-looking statements included in this press release are made only as of the date hereof. TRxADE cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. We undertake no obligation to update publicly any of these forward-looking statements to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable laws. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.
Media Contact:
Simone Valdez
IR@trxade.com
(800) 261-0281
Investor Relations:
Lucas Zimmerman, Senior Vice President
MZ Group - MZ North America
(949) 259-4987 | MEDS@mzgroup.us | www.mzgroup.us
SOURCE: TRxADE HEALTH, Inc.
View source version on accesswire.com:
https://www.accesswire.com/656387/Winn-Dixie-Southeastern-Grocers-Inc-and-Bonum-HealthTM-TRxADE-HEALTH-Company-Ink-Telemedicine-Deal
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
eComplete Partners with Sourceful to build AI-Native Creative Operations Across Portfolio18.11.2025 15:00:00 CET | Press release
MANCHESTER, UK / ACCESS Newswire / November 18, 2025 / eComplete, the private equity firm behind Current Body's £300 million London Stock Exchange listing, has announced a strategic partnership with Sourceful, the Manchester-based technology company whose Riverflow 1 model ranks as the world's leading AI image editing model. The partnership brings Sourceful's AI-native creative platform to eComplete's portfolio of direct-to-consumer brands, enabling them to generate brand-accurate, production-ready creative assets at scale across e-commerce, social, marketplace and retail. This makes eComplete the first major private equity investor to adopt AI-native creative infrastructure as a core operational advantage. Why this matters Every consumer brand today faces the same constraint: producing thousands of creative assets, product images, ads, videos, packaging, that feel authentically on-brand across every channel and market. This challenge has intensified dramatically over the past three ye
IXOPAY Appoints George Hansen as Chief Revenue Officer to Accelerate Global Growth in Tokenization, Orchestration, and Compliance18.11.2025 06:00:00 CET | Press release
Seasoned payments executive joins IXOPAY to lead global revenue strategy amid rapid growth and the rise of agentic commerce. LEHI, UTAH / ACCESS Newswire / November 18, 2025 / IXOPAY, a global leader in enterprise-grade payment orchestration, today announced the appointment of George Hansen as Chief Revenue Officer (CRO). A veteran of the payments and fintech industries, Hansen brings more than two decades of leadership experience driving growth, transformation, and customer-centric innovation at a global scale. In his new role, Hansen will drive IXOPAY's global revenue strategy, leading sales and partnerships and aligning with marketing and customer success to support enterprise merchants and partners worldwide. His appointment reinforces IXOPAY's commitment to giving merchants full control of their payment strategy through a vendor-neutral architecture designed for scale, flexibility, and intelligence. Hansen has held senior leadership positions at companies including American Expres
General Holdings Limited and NewOak Capital Form Strategic Joint Venture to Launch CMXG, an $800M Commodities Investment Platform18.11.2025 06:00:00 CET | Press release
DUBAI, AE / ACCESS Newswire / November 18, 2025 / General Holdings Limited (GH), a Dubai International Financial Centre-based multi-strategy private investment holding company, and NewOak Capital LLC, a New York collateralized private debt asset management and structured financing and capital markets firm, today announced the formation of Common Commodities CMXG (CMXG), a vertically integrated tech-enabled commodities investment platform designed to deliver risk-controlled, scalable institutional commodity-linked real yield and growth equity to qualified global investors. The partnership combines General Holdings' strategic capital and governance expertise with NewOak Capital's structured asset-based supply-chain financing capabilities and distribution platform. This sets the foundation for "a globally scalable, integrated and transparent institutional trade finance platform facilitating sustainable and inclusive cross-regional growth." Strategic Capital Deployment and Fund Launch CMXG
OBI-902 Has Been Granted by US FDA for Orphan Drug Designation for the Treatment of Cholangiocarcinoma17.11.2025 13:00:00 CET | Press release
OBI-902 is the first ADC utilizing OBI's proprietary GlycOBI® glycan-based ADC enabling technology for evaluation of safety and efficacy in patients with Cancer. TAIPEI, TW / ACCESS Newswire / November 17, 2025 / OBI Pharma, a clinical-stage oncology company (4174.TWO) received notification from the US FDA stating that the request for Orphan Drug Designation of OBI-902 TROP2 ADC for the treatment of Cholangiocarcinoma has been granted. OBI-902 is the first OBI-developed ADC that incorporates our proprietary site-specific glycan-conjugated ADC enabling technology. Cholangiocarcinoma is a rare and lethal malignancy with fewer than 50,000 patients in the United States and a 5-year survival rate ranging from 2% and 23% depending on disease stage, histological subtype, and localization 1 . At present, there are no FDA approved ADC therapies for cholangiocarcinoma. To encourage the industry to develop new treatment options for rare diseases, the US FDA grants Orphan Drug Designation to exper
Camino Completes C$5.6 Million Investment with Strategic Investors17.11.2025 12:00:00 CET | Press release
VANCOUVER, BC / ACCESS Newswire / November 17, 2025 / Camino Minerals Corporation (TSXV:COR)(OTC:CAMZF) ("Camino" or the "Company") is pleased to announce the closing of its -brokered private placement (the "Financing") of common shares in the capital of the Company (the "Shares") previously announced in its news release dated November 12, 2025. Under the Financing, the Company issued an aggregate of 15,554,666 Shares at an issue price of $0.36 per Share, for aggregate gross proceeds of C$5,599,680. Participants in the Financing included two new key shareholders, Elemental Royalties (formerly EMX Royalty Corp.) and Continental General Insurance Company, as well as certain insiders of Camino. The gross proceeds of the Financing will be applied towards corporate working capital, legal expenses, engineering studies, project development, and general administrative expenses. The Shares issued pursuant to the Financing are subject to a statutory hold period expiring on March 15, 2026, in acc
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
